Loading clinical trials...
Loading clinical trials...
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
Age
45 - 130 years
Sex
FEMALE
Healthy Volunteers
No
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Roeselare, Belgium
Research Site
Wilrijk, Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Cambridge, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Sault Ste. Marie, Ontario, Canada
Start Date
May 30, 2006
Primary Completion Date
June 13, 2008
Completion Date
March 13, 2019
Last Updated
January 6, 2020
144
ACTUAL participants
Fulvestrant
DRUG
Lead Sponsor
AstraZeneca
NCT06625775
NCT06649331
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions